Business & Industry

MSD has entered into a multi-year agreement with Google Cloud valued at up to $1 billion, enabling widespread deployment of advanced artificial intelligence tools across its global workforce of 75,000 employees. The collaboration will integrate Google Cloud’s agentic AI...

Royalties, milestone payments, and license fees are often treated as the cost of doing business in biopharma. But for early-stage biotech companies building toward an IND, these obligations can quietly reshape financial models, complicate investor conversations, and create downstream deal terms that are difficult to unwind. Here is what founders need to know.

AbbVie has outlined plans to build a major new manufacturing facility in Durham, committing $1.4 billion to what will become its largest single-campus capital investment to date. The project, spread across 185 acres, is expected to generate more than...

The Trump administration has introduced a new executive order designed to accelerate Psychedelic Drug Reviews, marking a notable policy move aimed at expediting regulatory pathways for emerging mental health treatments. The directive focuses on advancing FDA evaluation processes for...

Boehringer Ingelheim has introduced a new artificial intelligence (AI) and machine learning (ML) facility in London, strengthening its efforts to integrate advanced technologies into pharmaceutical research. The AI R&D centre will focus on applying AI models to support the...

Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could...

The U.S. Food and Drug Administration is preparing to revisit its stance on a group of peptide substances, as its Pharmacy Compounding Advisory Committee schedules a summer meeting that could influence how these products are regulated. The FDA advisory...